Opendata, web and dolomites

ONCOBIOME SIGNED

Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ONCOBIOME project word cloud

Explore the words cloud of the ONCOBIOME project. It provides you a very rough idea of what is the project "ONCOBIOME" about.

commensal    diagnosis    approvals    interdisciplinary    clinics    countries    breast    arsenal    retro    fda    campaigns    fingerprints    host    therapy    cancers    ancillary    frequent    physbeyond    oncogenesis    health    clinical    mode    prognosis    cohorts    cancer    types    lung    minimalist    oncological    ema    regulating    metabolomics    beyond    innovative    colorectal    multiple    preventive    gt    covariates    checkpoint    immunomics    relevance    dendritic    companion    neoplasia    adverse    action    hallmarks    decipher    trials    predict    oncology    genomics    ecosystems    unravel    urgent    platforms    initiation    integrate    biotics    inhibitors    progression    metabolism    therapies    enrolling    validation    optimal    experts    discovery    immunity    gut    melanoma    metagenome    functions    expects    pursue    signatures    cell    optimization    immune    intestinal    pro    patients    implicated    hence    spective    functionally    carat    core    validate    vaccines    oncobiome    ongoing    extraintestinal    personalization    polychemotherapy    plays    functional    regulation    adjusting    oncomicrobiome    tests    occurrence    microbiome    physiological    goms    lending    tools   

Project "ONCOBIOME" data sheet

The following table provides information about the project.

Coordinator
INSTITUT GUSTAVE ROUSSY 

Organization address
address: Rue Camille Desmoulins 39
city: VILLEJUIF
postcode: 94805
website: http://www.igr.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 14˙994˙551 €
 EC max contribution 14˙994˙551 € (100%)
 Programme 1. H2020-EU.3.1.2. (Preventing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT GUSTAVE ROUSSY FR (VILLEJUIF) coordinator 2˙332˙500.00
2    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 2˙801˙953.00
3    UNIVERSITA DEGLI STUDI DI TRENTO IT (TRENTO) participant 1˙502˙618.00
4    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 898˙275.00
5    Masarykova univerzita CZ (BRNO STRED) participant 885˙546.00
6    IIGM FOUNDATION IT (TORINO) participant 850˙436.00
7    UNIVERSITATSKLINIKUM ERLANGEN DE (ERLANGEN) participant 847˙125.00
8    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 791˙358.00
9    PHILIPPS UNIVERSITAET MARBURG DE (MARBURG) participant 703˙062.00
10    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 666˙498.00
11    GBG FORSCHUNGS GMBH DE (NEU-ISENBURG) participant 619˙312.00
12    HALIODX FR (MARSEILLE) participant 521˙322.00
13    EVERIMMUNE FR (VILLEJUIF) participant 519˙000.00
14    UNICANCER FR (PARIS) participant 431˙978.00
15    ALGOE SA FR (ECULLY CEDEX) participant 399˙812.00
16    FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI IT (Milan) participant 223˙750.00
17    CENTRE HOSPITALIER DE L'UNIVERSITEDE MONTREAL CA (MONTREAL QUEBEC) participant 0.00
18    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) participant 0.00

Map

 Project objective

Beyond the role the intestinal metagenome plays in regulating multiple physBeyond its role in regulating multiple physiological functions that impact health, the intestinal metagenome is implicated in cancer initiation, progression and responses to therapies, even for extraintestinal neoplasia. Hence, there is an urgent need to fully identify and functionally characterize minimalist commensal ecosystems relevant to cancer, with reliable and robust methods, to validate cancer-associated gut microbiome fingerprints of high clinical relevance, and to develop diagnosis tools that will become part of the oncological arsenal for the optimization and personalization of therapy. Based on retro-and pro-spective studies, with large discovery and validation cohorts enrolling >9,000 cancer patients across 10 countries, ancillary to ongoing innovative clinical trials or FDA/EMA approvals across 4 frequent cancer types, ONCOBIOME will pursue the following aims: 1/ identify and validate core or cancer-specific Gut OncoMicrobiome Signatures (GOMS) associated with cancer occurrence, prognosis, response to, or progression on, therapy (polychemotherapy, immune checkpoint inhibitors, dendritic cell vaccines) or adverse effects, 2/ decipher the functional relevance of these cancer-associated gut commensal ecosystems in the regulation of host metabolism, immunity and oncogenesis, 3/ integrate these GOMS with other oncology hallmarks (clinics, genomics, immunomics, metabolomics) 4/ design optimal companion tests, based on those integrated signatures to predict cancer occurrence and progression. With high carat interdisciplinary experts, ONCOBIOME expects to validate cancer or therapy-specific Gut OncoMicrobiome Signatures (GOMS) across breast, colorectal, melanoma and lung cancers adjusting for covariates, to unravel the mode of action of these GOMS in innovative platforms, thus lending support to the design of cancer preventive campaigns using well characterized pre-and pro-biotics.

 Deliverables

List of deliverables.
ONCOBIOME logo and graphic chart Websites, patent fillings, videos etc. 2020-02-18 10:08:13
Communication plan and website Documents, reports 2020-01-14 14:59:08

Take a look to the deliverables list in detail:  detailed list of ONCOBIOME deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOBIOME" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCOBIOME" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.2.)

ECRC (2019)

Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola

Read More  

HEAP (2020)

Human Exposome Assessment Platform

Read More  

EXIMIOUS (2020)

Mapping Exposure-Induced Immune Effects: Connecting the Exposome and the Immunome

Read More